Mineralys Therapeutics Advances Lorundrostat NDA Amid Q4 Earnings Beat

Mineralys Therapeutics has reached a critical inflection point in its corporate evolution, transitioning from a purely clinical-stage entity to one with a clear regulatory path toward commercialization. The company's Q4 2025 earnings report, which featured a GAAP EPS of -$0.40, outperformed analyst expectations by $0.13, signaling disciplined fiscal management as it scales operations. This financial performance is particularly noteworthy given the significant R&D investment required to move its lead candidate through the final stages of clinical development. The company's cash position remains a focal point for investors, as the transition to a commercial-stage organization will necessitate a significant build-out of sales and marketing infrastructure to compete in the crowded hypertension market.

The financial metrics remain secondary to the significant regulatory milestone announced concurrently: the FDA's acceptance of the New Drug Application (NDA) for lorundrostat. This lead candidate, a highly selective aldosterone synthase inhibitor (ASI), is positioned to address the massive and underserved market for uncontrolled or resistant hypertension. Unlike traditional mineralocorticoid receptor antagonists (MRAs), lorundrostat targets the enzyme responsible for aldosterone production itself. This mechanism of action is designed to provide potent blood pressure reduction while minimizing the risk of hyperkalemia, a common side effect of existing therapies. The EXPLORE-OSA data further expands the potential utility of the drug, suggesting benefits for patients whose hypertension is exacerbated by obstructive sleep apnea, a frequent comorbidity.

“

The company's Q4 2025 earnings report, which featured a GAAP EPS of -$0.40, outperformed analyst expectations by $0.13, signaling disciplined fiscal management as it scales operations.

Central to the company's long-term strategy are its ongoing Phase 3 trials, Launch-HTN and Transform-HTN. Launch-HTN is a pivotal study designed to evaluate the safety and efficacy of lorundrostat in patients with uncontrolled or resistant hypertension who are already on two or more antihypertensive medications. This trial is critical for establishing the drug's role as a potent add-on therapy for the millions of patients who fail to reach target blood pressure levels with current standards of care. Transform-HTN, on the other hand, focuses on a broader population, aiming to demonstrate the drug's utility across a wider range of patient demographics and baseline aldosterone levels. These trials are not just regulatory requirements; they are the foundation of the company's value proposition, providing the robust data package needed to compete with established standard-of-care treatments.